Zacks Investment Research downgraded shares of Citius Pharmaceuticals (NASDAQ:CTXR) from a hold rating to a sell rating in a research report report published on Monday, reports.

According to Zacks, “Citius Pharmaceuticals, Inc. is a specialty pharmaceutical company. It engaged in the development and commercialization of critical care products targeting medical needs with a focus on anti-infective products, adjunctive cancer care and prescription products. Citius Pharmaceuticals, Inc. is headquartered in Cranford, New Jersey. “

A number of other brokerages have also recently commented on CTXR. ValuEngine cut shares of Citius Pharmaceuticals from a buy rating to a hold rating in a report on Friday, December 21st. HC Wainwright reaffirmed a buy rating and set a $3.00 target price on shares of Citius Pharmaceuticals in a report on Thursday, February 7th.

Shares of CTXR stock opened at $1.20 on Monday. Citius Pharmaceuticals has a 12 month low of $0.86 and a 12 month high of $3.15.

A hedge fund recently bought a new stake in Citius Pharmaceuticals stock. Renaissance Technologies LLC purchased a new position in Citius Pharmaceuticals Inc (NASDAQ:CTXR) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 58,333 shares of the company’s stock, valued at approximately $100,000. Renaissance Technologies LLC owned 0.36% of Citius Pharmaceuticals at the end of the most recent reporting period. Hedge funds and other institutional investors own 5.01% of the company’s stock.

About Citius Pharmaceuticals

Citius Pharmaceuticals, Inc, a specialty pharmaceutical company, develops and commercializes critical care products. It primarily focuses on developing anti-infective, cancer care, and prescription products. The company develops Mino-Lok, which is in Phase III clinical trials for the treatment and salvage of infected central venous catheters in patients with catheter related bloodstream infections; and Hydro-Lido, a topical formulation of hydrocortisone and lidocaine that is intended for the treatment of hemorrhoids.

Featured Story: Quick Ratio

Get a free copy of the Zacks research report on Citius Pharmaceuticals (CTXR)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Citius Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Citius Pharmaceuticals and related companies with's FREE daily email newsletter.